{"title":"Evaluating the efficacy of radiotherapy in patients with embryonal tumor with multilayered rosettes: A systematic review and meta-analysis.","authors":"Harshal Shah, Evan Locke, Mason Henrich, Sidharth Anand, Tara Lozy, Nicholas DeNunzio, Derek Hanson","doi":"10.1093/nop/npae115","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Embryonal tumor with multilayered rosettes (ETMR) is a rare and deadly pediatric central nervous system tumor often seen before the age of 3. ETMR consists of embryonal tumors with abundant neuropil and true rosettes, ependymoblastoma, and medulloepithelioma. The 5-year survival rate has been reported to be between 0% and 30%. Treatment of ETMR is very unstandardized and typically consists of surgical resection, chemotherapy, and radiotherapy. A systematic review was performed to better understand treatment-related outcome trends.</p><p><strong>Methods: </strong>The authors performed a PRISMA guidelines-based systematic review of the literature. Survival curve analysis using Kaplan-Meier curves and Cox proportional hazards models were used to estimate survival rates between 2 groups and multiple risk factors, respectively.</p><p><strong>Results: </strong>The average survival time was 31.1 months in patients treated with radiotherapy compared to 11.2 months in patients who did not. Radiotherapy was a significant covariate on overall survival (<i>P</i> < .001) with an 82% lower risk of death compared to patients who did not receive radiotherapy. The average survival time for patients with focal radiotherapy was 35.8 months compared to 29.8 months in patients with CSI radiotherapy, but there was a great number of patients with pretreatment metastasis in the CSI group. In patients without pretreatment metastasis, focal radiotherapy had non-inferior outcomes for survival rates and times.</p><p><strong>Conclusions: </strong>Patients treated with radiotherapy in addition to chemotherapy demonstrated a significantly higher survival time. For patients with no metastasis prior to treatment, focal radiotherapy should be strongly considered.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 2","pages":"197-208"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Embryonal tumor with multilayered rosettes (ETMR) is a rare and deadly pediatric central nervous system tumor often seen before the age of 3. ETMR consists of embryonal tumors with abundant neuropil and true rosettes, ependymoblastoma, and medulloepithelioma. The 5-year survival rate has been reported to be between 0% and 30%. Treatment of ETMR is very unstandardized and typically consists of surgical resection, chemotherapy, and radiotherapy. A systematic review was performed to better understand treatment-related outcome trends.
Methods: The authors performed a PRISMA guidelines-based systematic review of the literature. Survival curve analysis using Kaplan-Meier curves and Cox proportional hazards models were used to estimate survival rates between 2 groups and multiple risk factors, respectively.
Results: The average survival time was 31.1 months in patients treated with radiotherapy compared to 11.2 months in patients who did not. Radiotherapy was a significant covariate on overall survival (P < .001) with an 82% lower risk of death compared to patients who did not receive radiotherapy. The average survival time for patients with focal radiotherapy was 35.8 months compared to 29.8 months in patients with CSI radiotherapy, but there was a great number of patients with pretreatment metastasis in the CSI group. In patients without pretreatment metastasis, focal radiotherapy had non-inferior outcomes for survival rates and times.
Conclusions: Patients treated with radiotherapy in addition to chemotherapy demonstrated a significantly higher survival time. For patients with no metastasis prior to treatment, focal radiotherapy should be strongly considered.
期刊介绍：
Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
